Close this search box.

Small-Cap Cancer Stocks

U.S. Exchanges

List of Publicly Traded Small-Cap Cancer Stocks Listed on Major U.S. Exchanges

This list includes small-sized companies with cancer related products with market capitalizations between 300 million and two billion dollars. We update this page at the start of every month so it is possible that during the course of a month a company’s market cap might fall below 300 million or go above two billion. In parentheses you will find a short description or areas of focus for the company.

Additional cancer focused companies can be found in our cancer section. A comparison widget that shows trend, earnings per share (EPS), P/E ratio and beta for each of the companies on this list can be accessed through the link below.

Small-Cap Cancer Industry Comparison Widget

Select the company’s link to access charts, news links and company website and social media information.

Cancer: Small-Cap Stocks

Acceleron Pharma Inc. (XLRN) (Cancer and orphan diseases)

Adaptimmune Therapeutics plc (ADAP) (IPO in May 2015, United Kingdom, biopharmaceutical company: cancer immunotherapy products)

Aduro BioTech, Inc. (ADRO) (IPO in April 2015: Cancer immunotherapy; pancreatic cancer)

Advaxis, Inc. (ADXS) (Clinical-stage biotechnology company: immunotherapies to treat cancer)

Agenus Inc. (AGEN) (Immunology: cancer, infectious diseases)

AngioDynamics, Inc. (ANGO) (Medical devices used treatment of cancer and peripheral vascular disease)

Arcus Biosciences, Inc. (RCUS) (IPO March 15, 2018; biopharmaceutical company: cancer immunotherapies)

argenx SE (ARGX) (IPO May 18, 2017; biotech company: autoimmune diseases and cancer)

ARMO BioSciences, Inc. (ARMO) (IPO January 26, 2018; immuno-oncology company)

Array BioPharma Inc. (ARRY) (Biopharmaceutical company: targeted small molecule drugs used to treat patients afflicted with cancer)

Atara Biotherapeutics, Inc. (ATRA) (Molecularly-targeted product candidates and T-cell product candidates; cancer, kidney disease and other illnesses)

Athenex, Inc. (ANTX) (IPO June 14, 2017; biopharmaceutical company: cancer)

Beigene, Ltd. (BGNE) (IPO February 3, 2016: Biopharmaceutical company with therapeutics designed to treat cancer)

Bellicum Pharmaceuticals, Inc. (BLCM) (Biopharmaceutical company: cellular immunotherapies for various forms of cancer; hematological and solid tumors, orphan inherited blood disorders)

BeyondSpring Inc. (BYSI) (IPO March 9, 2017; cancer therapies)

Blueprint Medicines Corporation (BPMC) (IPO in April 2015: Biopharmaceutical company: kinase inhibitors for genomically defined cancers)

Cellectis SA (CLLS) (IPO in March 2015, France: Gene-editing company; cancer therapies based on engineered T cells)

Celldex Therapeutics, Inc. (CLDX) (Therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines; brain cancer, triple negative breast cancer)

ChemoCentryx, Inc. (CCXI) (Biopharmaceutical company: orally-administered therapeutics for the treatment of autoimmune diseases, inflammatory disorders and cancer)

Corvus Pharmaceuticals, Inc. (CRVS) (IPO March 23, 2016: Biopharmaceutical company focused on immuno-oncology therapies for cancer)

Cue Biopharma, Inc. (CUE) (IPO January 2, 2018; biopharmaceutical company: cancer and autoimmune disorders)

Curis, Inc. (CRIS) (Drug candidates for the treatment of human cancers)

CytomX Therapeutics Inc. (CTMX) (IPO in October 2015: Biopharmaceutical company; antibody therapeutics, oncology)

Deciphera Pharmaceuticals, Inc. (DCPH) (IPO September 28, 2017; biopharmaceutical company: cancer)

Eagle Pharmaceuticals, Inc. (EGRX) (Injectable products: critical care and oncology)

Epizyme, Inc. (EPZM) (Biopharmaceutical company: therapeutics for patients with genetically defined cancers)

ERYTECH Pharma S.A. (ERYP) (IPO November 10, 2017; France: biopharmaceutical company: cancer)

FibroGen, Inc. (FGEN) (Biopharmaceutical company: anemia in chronic kidney disease, liver fibrosis, pancreatic cancer, corneal blindness)

G1 Therapeutics, Inc. (GTHX) (IPO May 17, 2017; biopharmaceutical company: cancer)

Geron Corporation (GERN) (Biopharmaceutical company: telomerase inhibitor in hematologic myeloid malignancies)

Halozyme Therapeutics, Inc. (HALO) (Oncology therapies that target the tumor microenvironment)

Heron Therapeutics, Inc. (HRTX) (Pharmaceutical products for patients suffering from cancer or pain)

Hutchison China MediTech Limited (HCM) (IPO March 17, 2016: Biopharmaceutical company focused on immunological diseases and oncology in addition to consumer health products)

Immunomedics, Inc. (IMMU) (Biopharmaceutical company: antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases)

Inovio Pharmaceuticals, Inc. (INO) (Cancer, infectious diseases, vaccines)

Iovance Biotherapeutics, Inc. (IOVA) (Immunotherapies based on tumor infiltrating lymphocytes)

Jounce Therapeutics, Inc. (JNCE) (IPO January 27, 2017; cancer immunotherapies)

Kadmon Holdings, Inc. (KDMN) (IPO July 27, 2016: biopharmaceutical company developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases)

Karyopharm Therapeutics Inc. (KPTI) (Drugs for the treatment of cancer and other major diseases)

Loxo Oncology, Inc. (LOXO) (Cancer therapies)

MacroGenics, Inc. (MGNX) (Biopharmaceutical company: monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases)

Merrimack Pharmaceuticals, Inc. (MACK) (Biopharmaceutical company: cancer)

Mersana Therapeutics, Inc. (MRSN) (IPO June 28, 2017; biopharmaceutical company: cancer)

Mesoblast Ltd. (MESO) (IPO in November 2015, Australia: regenerative medicine company; areas of focus include inflammation, cardiovascular disease and back pain)

Momenta Pharmaceuticals, Inc. (MNTA) (Therapeutics for oncology and autoimmune indications)

NewLink Genetics Corporation (NLNK) (Biopharmaceutical company: immunotherapy products, pancreatic cancer)

NovoCure Ltd. (NVCR) (IPO in October 2015, oncology company: treatment of solid tumor cancers)

NuCana plc (NCNA) (IPO September 28, 2017; biopharmaceutical company: medicines designed to overcome key cancer resistance mechanisms using proprietary ProTide technology)

Odonate Therapeutics, Inc. (ODT) (IPO December 7, 2017; pharmaceutical company: cancer)

OncoMed Pharmaceuticals, Inc. (OMED) (Biopharmaceutical company: antibody therapeutics targeting cancer stem cells)

Progenics Pharmaceuticals Inc. (PGNX) (Oncology company: diagnostic and therapeutic needs of prostate cancer patients)

PTC Therapeutics, Inc. (PTCT) (Biopharmaceutical company: oral treatments)

Puma Biotechnology Inc. (PBYI) (Biopharmaceutical company: products for the treatment of various forms of cancer)

Rigel Pharmaceuticals, Inc. (RIGL) (Small-molecule drugs for the treatment of immune diseases and cancers)

Spectrum Pharmaceuticals, Inc. (SPPI) (Hematology, oncology)

Syros Pharmaceuticals, Inc. (SYRS) (IPO June 30, 2016: Biopharmaceutical company, gene control medicines)

TG Therapeutics, Inc. (TGTX) (Biopharmaceutical company: B-cell malignancies and autoimmune diseases)

Unum Therapeutics Inc. (UMRX) (IPO March 29, 2018; biopharmaceutical company: immunotherapy products)

Xbiotech Inc. (XBIT) (Biopharmaceutical company: cancer antibodies)

Zai Lab Limited (ZLAB) (IPO September 20, 2017; biopharmaceutical company: autoimmune diseases, cancer, infectious diseases)

Ziopharm Oncology Inc. (ZIOP) (Biopharmaceutical company: cell-based therapies for the treatment of cancer)

Related Links:

List of Companies in the Healthcare Sector

List of Pharmaceutical Companies

List of Biotech Companies

List of Healthcare ETFs

List of Publicly Traded Companies